The agreement includes proposed biosimilars to Ilaris (canakinumab), Kesimpta (ofatumumab) and an additional early-stage undisclosed biosimilar candidate.
SteinCares will handle all regulatory filings, registrations and commercialization of Ranibizumab in Latin America, while Lupin will be responsible for manufacturing the same.